The clinicopathological characteristics with long-term outcomes in malignant mesothelioma


Dogan M., UTKAN G., Hocazade C., Uncu D., Toptas S., Ozdemir N., ...Daha Fazla

Medical Oncology, cilt.31, sa.10, ss.1-6, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 10
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12032-014-0232-0
  • Dergi Adı: Medical Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-6
  • Anahtar Kelimeler: Malignant mesothelioma, Mesothelioma, Prognostic factors in mesothelioma, MULTICENTER PHASE-II, PLEURAL MESOTHELIOMA, EXTRAPLEURAL PNEUMONECTOMY, PERITONEAL MESOTHELIOMA, GEMCITABINE, CISPLATIN, CHEMOTHERAPY, CANCER, RADIOTHERAPY, SURVIVAL
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

© 2014, Springer Science+Business Media New York.Malignant mesothelioma (MM) is a neoplasm which originates from serous membranes. It is relatively more common in Turkey. Ninety-nine patients between 2002–2009 were evaluated for survival and patient characteristics with chest pain, dyspnea, weight loss, loss of appetite, anemia, leukocytosis, thrombocytosis and lactate dehydrogenase (LDH) elevation, retrospectively. Male/female ratio was 1.41(58/41). Median age was 53(27–88). Asbestosis exposure rate was 78.5 %. Most of the patients had better ECOG-PS (88.7 % for 1–2). Chest pain (47.7 %), dyspnea (44.8 %), weight loss (49 %), loss of appetite (50 %), anemia (38 %), leukocytosis (37.2 %), thrombocytosis (26.6 %) and LDH elevation (10.1 %) were found with median values such as 11.8 g/dL (5–17.1) for hemoglobin, 8,800/mm3 for WBC (2,600–38,300), 382,000/mm3 for platelets (28,000–1,504,000) and 253 IU/L for LDH (85–1,877), respectively. The most common site was pleura (62.3 %). Half of the patients were unclassified, while epitheloid histopathology (39.4 %) was most common in classified ones. RT rate was 42.1 % in operated patients and all had pleural MM. Median OS was 22.9 months. Eighty percent of the patients had first-line CT with a clinical benefit rate of 63.3 %. Second-line CT rate was 29 % with a clinical benefit rate of 44 %. Most preferred CT regimen was cisplatinum and pemetrexed. Most of the patients were male in their 50 s with pleural MM. They had chest pain, dyspnea, weight loss and loss of appetite as the most common symptoms at diagnosis. Only half of the patients could be subtyped with a predominance of epitheloid histology.